Thymidine-dependent Staphylococcus aureus small-colony variants are induced by trimethoprim-sulfamethoxazole (SXT) and have increased fitness during SXT challenge

Andre Kriegeskorte, Nicola Ivan Lorè, Alessandra Bragonzi, Camilla Riva, Marco Kelkenberg, Karsten Becker, Richard A. Proctor, Georg Peters, Barbara C. Kahl

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Trimethoprim-sulfamethoxazole (SXT) is a possible alternative for the treatment of community- and hospital-acquired methicillin- resistant Staphylococcus aureus (MRSA) due to the susceptibility of most MRSA strains to the drug. However, after longterm treatment with SXT, thymidine-dependent (TD) SXT-resistant small-colony variants (SCVs) emerge. In TD-SCVs, mutations of thymidylate synthase ([TS] thyA) occur. Until now, it has never been systematically investigated that SXT is triggering the induction and/or selection of TD-SCVs. In our study, we performed induction, reversion, and competition experiments in vitro and in vivo using a chronic mouse pneumonia model to determine the impact of SXT on the emergence of TD-SCVs. SCVs were characterized by light and transmission electron microscopy (TEM) and auxotrophism testing. Short-term exposure of S. aureus to SXT induced the TD-SCV phenotype in S. aureus SH1000, while selection of TD-SCVs with thyA mutations occurred after long-term exposure. In reversion experiments with clinical and laboratory TD-SCVs, all revertants carried compensating mutations at the initially identified mutation site. Competition experiments in vitro and in vivo revealed a survival and growth advantage of the ΔthyA mutant under low-thymidine availability and SXT exposure although this advantage was less profound in vivo. Our results show that SXT induces the TD-SCV phenotype after short-term exposure, while long-term exposure selects for thyA mutations, which provide an advantage for TD-SCVs under specified conditions. Thus, our results further an understanding of the dynamic processes occurring during SXT exposure with induction and selection of S. aureus TD-SCVs.

Original languageEnglish
Pages (from-to)7265-7272
Number of pages8
JournalAntimicrobial Agents and Chemotherapy
Volume59
Issue number12
DOIs
Publication statusPublished - Dec 1 2015

Fingerprint

Sulfamethoxazole Drug Combination Trimethoprim
Thymidine
Staphylococcus aureus
Mutation
Methicillin-Resistant Staphylococcus aureus
Phenotype
Thymidylate Synthase
Community Hospital
Transmission Electron Microscopy
Pneumonia
Light

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Thymidine-dependent Staphylococcus aureus small-colony variants are induced by trimethoprim-sulfamethoxazole (SXT) and have increased fitness during SXT challenge. / Kriegeskorte, Andre; Lorè, Nicola Ivan; Bragonzi, Alessandra; Riva, Camilla; Kelkenberg, Marco; Becker, Karsten; Proctor, Richard A.; Peters, Georg; Kahl, Barbara C.

In: Antimicrobial Agents and Chemotherapy, Vol. 59, No. 12, 01.12.2015, p. 7265-7272.

Research output: Contribution to journalArticle

Kriegeskorte, Andre ; Lorè, Nicola Ivan ; Bragonzi, Alessandra ; Riva, Camilla ; Kelkenberg, Marco ; Becker, Karsten ; Proctor, Richard A. ; Peters, Georg ; Kahl, Barbara C. / Thymidine-dependent Staphylococcus aureus small-colony variants are induced by trimethoprim-sulfamethoxazole (SXT) and have increased fitness during SXT challenge. In: Antimicrobial Agents and Chemotherapy. 2015 ; Vol. 59, No. 12. pp. 7265-7272.
@article{2ab926a3f450484bb5e0fee2eb481e8f,
title = "Thymidine-dependent Staphylococcus aureus small-colony variants are induced by trimethoprim-sulfamethoxazole (SXT) and have increased fitness during SXT challenge",
abstract = "Trimethoprim-sulfamethoxazole (SXT) is a possible alternative for the treatment of community- and hospital-acquired methicillin- resistant Staphylococcus aureus (MRSA) due to the susceptibility of most MRSA strains to the drug. However, after longterm treatment with SXT, thymidine-dependent (TD) SXT-resistant small-colony variants (SCVs) emerge. In TD-SCVs, mutations of thymidylate synthase ([TS] thyA) occur. Until now, it has never been systematically investigated that SXT is triggering the induction and/or selection of TD-SCVs. In our study, we performed induction, reversion, and competition experiments in vitro and in vivo using a chronic mouse pneumonia model to determine the impact of SXT on the emergence of TD-SCVs. SCVs were characterized by light and transmission electron microscopy (TEM) and auxotrophism testing. Short-term exposure of S. aureus to SXT induced the TD-SCV phenotype in S. aureus SH1000, while selection of TD-SCVs with thyA mutations occurred after long-term exposure. In reversion experiments with clinical and laboratory TD-SCVs, all revertants carried compensating mutations at the initially identified mutation site. Competition experiments in vitro and in vivo revealed a survival and growth advantage of the ΔthyA mutant under low-thymidine availability and SXT exposure although this advantage was less profound in vivo. Our results show that SXT induces the TD-SCV phenotype after short-term exposure, while long-term exposure selects for thyA mutations, which provide an advantage for TD-SCVs under specified conditions. Thus, our results further an understanding of the dynamic processes occurring during SXT exposure with induction and selection of S. aureus TD-SCVs.",
author = "Andre Kriegeskorte and Lor{\`e}, {Nicola Ivan} and Alessandra Bragonzi and Camilla Riva and Marco Kelkenberg and Karsten Becker and Proctor, {Richard A.} and Georg Peters and Kahl, {Barbara C.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1128/AAC.00742-15",
language = "English",
volume = "59",
pages = "7265--7272",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "12",

}

TY - JOUR

T1 - Thymidine-dependent Staphylococcus aureus small-colony variants are induced by trimethoprim-sulfamethoxazole (SXT) and have increased fitness during SXT challenge

AU - Kriegeskorte, Andre

AU - Lorè, Nicola Ivan

AU - Bragonzi, Alessandra

AU - Riva, Camilla

AU - Kelkenberg, Marco

AU - Becker, Karsten

AU - Proctor, Richard A.

AU - Peters, Georg

AU - Kahl, Barbara C.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Trimethoprim-sulfamethoxazole (SXT) is a possible alternative for the treatment of community- and hospital-acquired methicillin- resistant Staphylococcus aureus (MRSA) due to the susceptibility of most MRSA strains to the drug. However, after longterm treatment with SXT, thymidine-dependent (TD) SXT-resistant small-colony variants (SCVs) emerge. In TD-SCVs, mutations of thymidylate synthase ([TS] thyA) occur. Until now, it has never been systematically investigated that SXT is triggering the induction and/or selection of TD-SCVs. In our study, we performed induction, reversion, and competition experiments in vitro and in vivo using a chronic mouse pneumonia model to determine the impact of SXT on the emergence of TD-SCVs. SCVs were characterized by light and transmission electron microscopy (TEM) and auxotrophism testing. Short-term exposure of S. aureus to SXT induced the TD-SCV phenotype in S. aureus SH1000, while selection of TD-SCVs with thyA mutations occurred after long-term exposure. In reversion experiments with clinical and laboratory TD-SCVs, all revertants carried compensating mutations at the initially identified mutation site. Competition experiments in vitro and in vivo revealed a survival and growth advantage of the ΔthyA mutant under low-thymidine availability and SXT exposure although this advantage was less profound in vivo. Our results show that SXT induces the TD-SCV phenotype after short-term exposure, while long-term exposure selects for thyA mutations, which provide an advantage for TD-SCVs under specified conditions. Thus, our results further an understanding of the dynamic processes occurring during SXT exposure with induction and selection of S. aureus TD-SCVs.

AB - Trimethoprim-sulfamethoxazole (SXT) is a possible alternative for the treatment of community- and hospital-acquired methicillin- resistant Staphylococcus aureus (MRSA) due to the susceptibility of most MRSA strains to the drug. However, after longterm treatment with SXT, thymidine-dependent (TD) SXT-resistant small-colony variants (SCVs) emerge. In TD-SCVs, mutations of thymidylate synthase ([TS] thyA) occur. Until now, it has never been systematically investigated that SXT is triggering the induction and/or selection of TD-SCVs. In our study, we performed induction, reversion, and competition experiments in vitro and in vivo using a chronic mouse pneumonia model to determine the impact of SXT on the emergence of TD-SCVs. SCVs were characterized by light and transmission electron microscopy (TEM) and auxotrophism testing. Short-term exposure of S. aureus to SXT induced the TD-SCV phenotype in S. aureus SH1000, while selection of TD-SCVs with thyA mutations occurred after long-term exposure. In reversion experiments with clinical and laboratory TD-SCVs, all revertants carried compensating mutations at the initially identified mutation site. Competition experiments in vitro and in vivo revealed a survival and growth advantage of the ΔthyA mutant under low-thymidine availability and SXT exposure although this advantage was less profound in vivo. Our results show that SXT induces the TD-SCV phenotype after short-term exposure, while long-term exposure selects for thyA mutations, which provide an advantage for TD-SCVs under specified conditions. Thus, our results further an understanding of the dynamic processes occurring during SXT exposure with induction and selection of S. aureus TD-SCVs.

UR - http://www.scopus.com/inward/record.url?scp=84954528065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954528065&partnerID=8YFLogxK

U2 - 10.1128/AAC.00742-15

DO - 10.1128/AAC.00742-15

M3 - Article

AN - SCOPUS:84954528065

VL - 59

SP - 7265

EP - 7272

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 12

ER -